Compare Southern Copper Corp (SCCO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Summit Therapeutics Inc — how do they compare? Southern Copper Corp trades at $209.75 (market cap $167.74B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Southern Copper Corp is far larger — about 12.2× Summit Therapeutics Inc's market cap, and Southern Copper Corp pays a 2.21% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southern Copper Corp for 61 Days and Summit Therapeutics Inc for 16 Days on average.
| SCCO | SMMT | |
|---|---|---|
Market Cap | $167.74B | $13.71B |
Volume | 853,110 | 6,173,057 |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $26.38 |
52-Week Low | $120.02 | $12.43 |
Typical Hold Time | 61 Days | 16 Days |
Enterprise Value | $169.03B | $13.04B |
Dividend Yield | 2.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $209.21, up 4.31% with strong earnings momentum, beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 35.87% net margins and 50.07% ROE. Recent news highlights the company's $10.2B Mexican project pipeline as a long-term growth driver while current sentiment remains mixed amid copper price volatility.
SCCO presents a valuation premium with P/E of 29.81 and P/S of 10.72, trading above analyst consensus target of $167.67. While operational excellence and project pipeline support upside potential, elevated valuation and bearish technicals suggest near-term caution. The stock faces headwinds from copper market volatility and competitive pressures in the materials sector.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
